Journal
VIRUSES-BASEL
Volume 15, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/v15030614
Keywords
long COVID; monoclonal antibodies; resistance; post-exposure treatment
Categories
Ask authors/readers for more resources
This study presents the case of a 76-year-old male patient with persistent infection of SARS-CoV-2 in the context of cutaneous melanoma and non-Hodgkin's lymphoma. Cancer treatments were discontinued due to persistent COVID-19. The patient was treated with sotrovimab, but acquired resistance mutations made it ineffective. In vitro screening of Evusheld monoclonal antibodies against the patient's viral strains led to successful therapy and allowed the patient to resume cancer treatment.
We present the case of a 76-year-old male patient persistently infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the setting of a stage IIIC cutaneous melanoma and non-Hodgkin's lymphoma (NHL). Due to the persistent coronavirus disease 19 (COVID-19), all cancer treatments were discontinued. Because of the worsening of his clinical state and the persistence of SARS-CoV-2 positivity for more than six months, the patient was treated with sotrovimab, which was ineffective due to resistance mutations acquired during that time. In order to resume cancer treatment and make the patient free from SARS-CoV-2, an in vitro screening of Evusheld monoclonal antibodies (tixagevumab-cilgavimab) against the viral strains isolated from the subject was performed. The promising results obtained during in vitro testing led to the authorization of the off-label use of Evusheld, which made the patient negative for SARS-CoV-2, thus, allowing him to resume his cancer treatment. This study highlights the Evusheld monoclonal antibodies' efficacy, not only in prevention but also in successful therapy against prolonged COVID-19. Therefore, testing neutralizing monoclonal antibodies in vitro against SARS-CoV-2 mutants directly isolated from patients could provide useful information for the treatment of people affected by long COVID.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available